FAIR PRICING FOR RARE DISEASE DRUGS: two truths operate here. First, innovators must be incentivized. Second, prices are way out of line. One approach for consideration by pricing agencies is to take the sum an innovator invested, and set the return on investment in line with a mean of brand Pharma. That way benchmarks fairness to both the Pharma company and to patients.